Skip to main content
Clinical Trials/EUCTR2006-003381-33-SI
EUCTR2006-003381-33-SI
Active, not recruiting
Not Applicable

Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.

Institute of Oncology Ljubljana0 sitesAugust 31, 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Inoperable squamous cell carcinoma of the head and neck.
Sponsor
Institute of Oncology Ljubljana
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 31, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Squamous cell carcinoma, histologically proven.
  • \- Tumor site: oral cavity, oropharynx, hypopharynx, or larynx.
  • \- Locally and/or regionally inoperable tumors (UICC TNM stages IVa or IVb), without distant metastases (M0\-stage); criteria for inoperability:
  • \-\-\> Technical unresectability,
  • \-\-\> Tumor fixation to the clavicle, base of skull or the cervical vertebrae,
  • \-\-\> Involvement of the nasopharynx or carotid artery.
  • \- Declaration of the inoperability of the patient given by a head and neck surgeon and radiation oncologist at the multidisciplinary tumor conference.
  • \- Male or female \=18 years of age.
  • \- Expected survival \> 6 months.
  • \- Presence of at least one bidimensionally measurable index lesion.

Exclusion Criteria

  • \- Metastatic disease.
  • \- Squamous cell carcinoma of the nasopharynx and nasal cavity and paranasal sinuses.
  • \- ChT or XRT ineligibility:
  • \-\-\> Unstable cardiac disease or any other medical condition likely to compromise the safe delivery of ChT or XRT;
  • \-\-\> Clinically evident hearing impairment;
  • \-\-\> Pre\-existing motor or sensory neurotoxicity grade \= 2 according to the CTCAE v3\.0\.
  • \- Any kind of previous therpay for SCCHN (excluding diagnostic biopsy).
  • \- Previous administration of EGFR pathway\-tergeting therapy.
  • \- Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy which is not part of the study protocol.
  • \- Participation in another clinical trial within 30 days prior to study entry.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Radiotherapy following induction chemotherapy in locally advanced, unresectable pancreatic cance-a randomised phase 3 trial:Radiotherapy following induction chemotherapy compared with chemotherapy alone.
EUCTR2009-014476-21-DEDekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. med. Markus F. Neurath830
Active, not recruiting
Phase 1
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01Cervical CancerMedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008236Term: Cervical cancer stage IV Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008235Term: Cervical cancer stage III Class: 10029104Therapeutic area: Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]Therapeutic area: Phenomena and Processes [G] - Reproductive and Urinary Physiological Phenomena [G08]
CTIS2024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
Suspended
Phase 3
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01
2024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
Completed
Not Applicable
Induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2)/IIIB non-small cell lung cancer
JPRN-UMIN000006022Iseikai Hospital45
Active, not recruiting
Not Applicable
INDUCTION CHEMOTHERAPY FOLLOWED BY RADIOTHERAPY CONCOMITANT TO CETUXIMAB IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: PHASE II STUDY - NDhead and neck squamous cell carcinomaMedDRA version: 9.1Level: HLTClassification code 10046311Term: Upper respiratory tract neoplasms
EUCTR2007-004099-38-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO